Presentations at major conferences often lead to increased visibility and interest in a company's work, which can positively impact the company's stock price. Given that Taysha Gene Therapies is presenting on TSHA-102, a therapy for Rett Syndrome, this could potentially attract attention from investors interested in biotech and gene therapy, leading to a positive impact on the company's stock price.